Bioimpacts of anti epidermal growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells

Journal of Biomedical Nanotechnology

Volumn 6, Issue 4, 2010, Pages 360-369

  Nakhlband, Ailar ^a,b   Barar, Jaleh ^a   Bidmeshkipour, Ali ^b   Heidari, Hamid Reza ^a   Omidi, Yadollah ^a,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b RAZI UNIVERSITY   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytotoxicity; Dendrimers; Epidermal growth factor receptor; Gene delivery nanosystem; Genotoxicity

Indexed keywords

A549 CELLS; ADENOCARCINOMA CELLS; ANTI-EGFR; ANTISENSE; CANCEROUS CELLS; COMET ASSAYS; DNA DAMAGES; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTORS; GENE DELIVERY NANOSYSTEM; GENOTOXICITIES; GROWTH REDUCTION; HUMAN LUNG; LUNG CANCER; MTT ASSAYS; PAMAM DENDRIMER; POLYAMIDOAMINE DENDRIMERS; TARGET CELLS; TRANSFECTION EFFICIENCY;

BIOLOGICAL ORGANS; CELL GROWTH; DISEASES; ENZYMES; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GROWTH KINETICS; NANOSYSTEMS; PEPTIDES; ZETA POTENTIAL;

DENDRIMERS;

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCL2 RELATED PROTEIN A1; BETA ACTIN; CATHEPSIN G; CYCLIN A; DENDRIMER; DNA POLYMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; NANOPARTICLE; POLYAMIDOAMINE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN S6; RIBOSOME PROTEIN; ANTISENSE OLIGONUCLEOTIDE; PEI PAMAM; PEI-PAMAM; POLYAMINE;

ARTICLE; CANCER CELL; CELL CULTURE; CELL GROWTH; CELL VIABILITY; CHROMOSOME SEGREGATION; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA MICROARRAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GEL ELECTROPHORESIS; GENE EXPRESSION; GENE SEQUENCE; GENOTOXICITY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; MICROARRAY ANALYSIS; PARTICLE SIZE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZETA POTENTIAL; ADENOCARCINOMA; CELL SURVIVAL; DRUG EFFECT; FLUORESCENCE; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETICS; LUNG TUMOR; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DENDRIMERS; FLOW CYTOMETRY; FLUORESCENCE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICROARRAY ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; POLYAMINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79953002759     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1131     Document Type: Article

References (45)

1. B. Fischer, M. Marinov, and A. Arcaro, Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far? Cancer Treat. Rev. 33, 391 (2007).
2. C. T. Kuo, M. J. Hsu, B. C. Chen, C. C. Chen, C. M. Teng, S. L. Pan, and C. H. Lin, Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction. Toxicol. Lett. 177, 48 (2008).
3. W. Lei, J. E. Mayotte, and M. L. Levitt, EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells. Biochem. Biophy. Res. Commun. 245, 939 (1998).
4. M. Reck and L. Crino, Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 63, 1 (2009).
5. J. Majidi, J. Barar, B. Baradaran, J. Abdolalizadeh, and Y. Omidi, Target therapy of cancer: Implementation of monoclonal antibodies and nanobodies. Hum. Antibodies 18, 81 (2009).
6. S. Abu-Ali, A. Fotovati, and K. Shirasuna, Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers. Mol. Cancer 7, 47 (2008).
7. S. Agelaki, M. Spiliotaki, H. Markomanolaki, G. Kallergi, D. Mavroudis, V. Georgoulias, and C. Stournaras, Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol. Ther. 8, 15 (2009).
8. W. Messersmith, D. Oppenheimer, J. Peralba, V. Sebastiani, M. Amador, A. Jimeno, E. Embuscado, M. Hidalgo, and C. Iacobuzio-Donahue, Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biol. Ther. 4, 1381 (2005).
9. G. P. Amorino, P. D. Deeble, and S. J. Parsons, Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene 26, 745 (2007).
10. W. E. Sweeney, Jr. and E. D. Avner, Molecular, and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD). Cell Tissue Res. 326, 671 (2006).
11. Z. Suo, E. Karbovo, C. G. Trope, K. Metodiev, and J. M. Nesland, Papillary serous carcinoma of the ovary: An ultrastructural and immunohistochemical study. Ultrastruct. Pathol. 28, 141 (2004).
12. C. Athale, Y. Mansury, and T. S. Deisboeck, Simulating the impact of a molecular 'decision-process' on cellular phenotype and multicellular patterns in brain tumors. J. Theor. Biol. 233, 469 (2005).
13. F. Schonleben, J. D. Allendorf, W. Qiu, X. Li, D. J. Ho, N. T. Ciau, R. L. Fine, J. A. Chabot, H. E. Remotti, and G. H. Su, Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas 36, 168 (2008).
14. R. Alonzi and P. Hoskin, Novel therapies in bladder cancer. Clin. Oncol. (R. Coll. Radiol.) 17, 524 (2005).
15. F. Afaq, N. Zaman, N. Khan, D. N. Syed, S. Sarfaraz, M. A. Zaid, and H. Mukhtar, Inhibition of epidermal growth factor receptor signaling pathway by delphinidin, an anthocyanidin in pigmented fruits and vegetables. Int. J. Cancer 123, 1508 (2008).
16. E. R. Camp, J. Summy, T. W. Bauer, W. Liu, G. E. Gallick, and L. M. Ellis, Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin. Cancer Res. 11, 397 (2005).
17. S. Loew, U. Schmidt, A. Unterberg, and M. E. Halatsch, The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med. Chem. 9, 703 (2009).
18. C. Mamot and C. Rochlitz, Targeting the epidermal growth factor receptor (EGFR) - a new therapeutic option in oncology? Swiss. Med. Wkly. 136, 4 (2006).
19. C. Gialeli, D. Kletsas, D. Mavroudis, H. P. Kalofonos, G. N. Tzanakakis, and N. K. Karamanos, Targeting epidermal growth factor receptor in solid tumors: Critical evaluation of the biological importance of therapeutic monoclonal antibodies. Curr. Med. Chem. 16, 3797 (2009).
20. N. H. Andratschke, K. H. Dittmann, K. A. Mason, Z. Fan, Z. Liao, R. Komaki, K. K. Ang, and L. Milas, Epidermal growth factor recep- tor as a target to improve treatment of lung cancer. Clin. Lung Cancer 5, 340 (2004).
21. Y. Omidi and J. Barar, Induction of human alveolar epithelial cell growth factor receptors by dendrimeric nanostructures. Int. J. Toxicol. 28, 113 (2009).
22. A. J. Hollins, Y. Omidi, I. F. Benter, and S. Akhtar, Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J. Drug Target. 15, 83 (2007).
23. Y. Omidi, A. J. Hollins, R. M. Drayton, and S. Akhtar, Polypropylenimine dendrimer-induced gene expression changes: The effect of complexation with DNA, dendrimer generation and cell type. J. Drug Target. 13, 431 (2005).
24. Y. Omidi, J. Barar, and S. Akhtar, Toxicogenomics of cationic lipid-based vectors for gene therapy: Impact of microarray technology. Curr. Drug Deliv. 2, 429 (2005).
25. Y. Omidi, J. Barar, H. R. heidari, S. Ahmadian, H. Ahmadpour Yazdi, and S. Akhtar, Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial A549 cells. Toxicol. Mech. Meth. 18, 369 (2008).
26. S. Zhang, B. Zhao, H. Jiang, B. Wang, and B. Ma, Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control. Release 123, 1 (2007).
27. R. Duncan and L. Izzo, Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57, 2215 (2005).
28. L. Albertazzi, M. Serresi, A. Albanese, and F. Beltram, Dendrimer internalization and intracellular trafficking in living cells. Mol. Pharm. 7, 680 (2010).
29. K. M. Kitchens, A. B. Foraker, R. B. Kolhatkar, P. W. Swaan, and H. Ghandehari, Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm. Res. 24, 2138 (2007).
30. G. Beale, A. J. Hollins, M. Benboubetra, M. Sohail, S. P. Fox, I. Benter, and S. Akhtar, Gene silencing nucleic acids designed by scanning arrays: Anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J. Drug Target. 11, 449 (2003).
31. M. Zhang, X. Zhang, C. X. Bai, X. R. Song, J. Chen, L. Gao, J. Hu, Q. Y. Hong, M. J. West, and M. Q. Wei, Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer. Genet. Vaccines Ther. 3, 1 (2005).
32. F. Deng, Y. Wang, F. Y. Zeng, Z. P. Zou, X. C. Bai, D. Lu, Z. Y. Ke, and S. Q. Luo, Antisense epidermal growth factor receptor (EGFR) transfection down-regulates EGFR expression and suppresses the malignant phenotype of human nasopharyngeal carcinoma CNE-2 cell line. Acad. J. First Med. Coll. PLA 23, 877 (2003).
33. Z. B. Gong, J. M. Liu, and Y. M. Li, Inhibitory effect of EGFR antisense oligodeoxynucleotide on human hepatoma cell line. Hepat. Panc. Disease. Internat. 4, 433 (2005).
34. C. S. Kang, Z. Y. Zhang, Z. F. Jia, G. X. Wang, M. Z. Qiu, H. X. Zhou, S. Z. Yu, J. Chang, H. Jiang, and P. Y Pu, Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther. 13, 530 (2006).
35. W. H. Fan, Y. L. Lu, F. Deng, X. M. Ge, S. Liu, and P. H. Tang, EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells. Cell Res. 8, 63 (1998).
36. T. L. Bowles, C. Parsons, D. J. Muilenburg, and R. J. Bold, Targeted inhibition of AKT in pancreatic cancer. Curr. Cancer Ther. Rev. 5, 288 (2009).
37. H. Kuroda, M. Takeno, S. Murakami, N. Miyazawa, T. Kaneko, and Y. Ishigatsubo, Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. Lung Cancer 67, 31 (2010).
38. L. Qiao and B. C. Y. Wong, Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist. Updat. 12, 55 (2009).
39. Y. Ping, Z. Jian, Z. Yi, Z. Huoyu, L. Feng, Y. Yuqiong, and L. Shixi, Inhibition of the EGFR with nanoparticles encapsulating antisense oligonucleotides of the EGFR enhances radiosensitivity in SCCVII cells. Med. Oncol. 27, 3 (2010).
40. A. Karsan, E. Yee, and J. M. Harlan, Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. J. Biol. Chem. 271, 27201 (1996).
41. S. S. Choi, I. C. Park, J. W. Yun, Y. C. Sung, S. I. Hong, and H. S. Shin, A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 11, 1693 (1995).
42. E. Armstrong, L. Cannizzaro, M. Bergman, K. Huebner, and K. Alitalo, The c-src tyrosine kinase (CSK) gene, a potential antioncogene, localizes to human chromosome region 15q23- q25. Cytogenet. Cell Genet. 60, 119 (1992).
43. H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan, Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100 (2006).
44. M. H. Han, J. Chen, J. Wang, S. L. Chen, and X. T. Wang, Blood compatibility of polyamidoamine dendrimers and erythrocyte protection. J. Biomed. Nanotechnol. 6, 82 (2010).
45. A. J. Hollins, M. Benboubetra, Y. Omidi, B. H. Zinselmeyer, A. G. Schatzlein, I. F. Uchegbu, and S. Akhtar, Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. Pharm Res. 21, 458 (2004).